CeraVe, a leading skincare brand, is currently facing at least six federal class-action lawsuits alleging that its benzoyl peroxide (BPO) acne treatment products contain unsafe levels of benzene, a known human carcinogen. These legal actions follow independent laboratory Valisure's findings, which reported benzene levels in certain CeraVe products exceeding the FDA's conditional limit of 2 parts per million (ppm). The lawsuits specifically target CeraVe Acne Foaming Cream Cleanser (4% BPO) and CeraVe Acne Foaming Cream Wash (10% BPO).
Valisure, an independent quality advocate, submitted a citizen petition to the FDA in March 2024, detailing that benzoyl peroxide, the active ingredient in these products, can degrade into benzene, particularly when exposed to heat. Their testing indicated benzene concentrations as high as 12 ppm in some CeraVe products. Benzene is classified as a Group 1 human carcinogen, linked to serious conditions such as leukemia, non-Hodgkin's lymphoma, and multiple myeloma, with no safe exposure level.
In contrast, the U.S. Food and Drug Administration (FDA) announced in March 2025 the results of its own testing on 95 benzoyl peroxide products. The agency stated that over 90% of the tested products had undetectable or extremely low levels of benzene. The FDA initiated voluntary recalls for only six products from five brands, including La Roche-Posay and Proactiv, but CeraVe products were not among those recalled by the FDA. The FDA also expressed concern that "use of unvalidated testing methods by third-party laboratories can produce inaccurate results leading to consumer confusion."
The lawsuits, filed against CeraVe's parent company L'Oréal, claim the company failed to warn consumers about the potential for benzene formation. Plaintiffs argue that L'Oréal "knew or should have known" about the instability of benzoyl peroxide. These legal challenges highlight a significant discrepancy between independent lab findings and regulatory agency assessments regarding the safety of popular acne treatments. The ongoing litigation seeks to represent consumers who purchased these products, alleging they would not have done so had they been aware of the benzene risk.
